Lilly's interleukin IL-17A antagonist, Taltz, is settling on its prescription area at general hospitals.

According to the related industry on the 6th, psoriasis treatment Taltz (Ixekizumab) passed the drug commitee (DC) of Seoul National Hospital recently after Asan Hospital and Severance Hospital among the Big Five. In addition, prescription codes have been made into major hospitals such as Seoul National University Bundang Hospital and Pusan ​​National University Hospital.

Taltz, which was released in late 2018, was slower to be priscribed in general hospitals compared to Janssen's IL-23 antagonist Tremfya (Guselkumab), which had entered the same period.

Nov